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1 |  INTRODUCTION
Breast cancer (BC) is the most common cancer among 
women worldwide, accounting for 25% of all new female 
cancer cases in 2012.1 Survival rates in Europe have in-
creased through screening and improved treatment. However, 
despite the success, there might be unintended complications 
associated with adjuvant chemotherapy and/or aromatase 
inhibitors, since some women with BC experience adverse 
long‐term metabolic effects.2
Adjuvant or neoadjuvant chemotherapy, which is cyto-
toxic to tumor cells, is most often given as a combination 
of drugs. The most common regimens include sequential 
anthracycline‐cyclophosphamide and taxane (AC‐T); con-
current anthracycline‐cyclophosphamide and taxane (ACT); 
anthracycline‐cyclophosphamide without taxane (AC); cy-
clophosphamide, methotrexate, and fluorouracil (CMF); and 
docetaxel and cyclophosphamide (TC).3 Aromatase inhibi-
tors are the first hormonal therapy medicine choice for post-
menopausal women whereas tamoxifen, which is a selective 
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Abstract
Introduction: Breast cancer (BC) is the most common cancer among women world-
wide. With increasing survival rates, focus has expanded to long‐term adverse ef-
fects of adjuvant chemotherapy and/or aromatase inhibitors. Weight gain during 
chemotherapy has been well documented, but the underlying mechanisms remain 
unclear. A change in glucose and insulin metabolism is a possible consequence.
Methods: We searched PubMed on the 4th of May 2018, and found eight articles 
that compared measurements of glucose and insulin before and after chemotherapy 
and/or aromatase inhibitors in woman with BC.
Results: A general trend of increased glucose and insulin is seen and likely to be 
caused by weight gain and/or changes in body composition as a consequence of ad-
juvant treatment of BC.
Discussion: Due to methodological limitations including short follow‐up times and 
small sample sizes, further studies are required to better describe metabolic conse-
quences of adjuvant chemotherapy and/or aromatase inhibitors. Future studies could 
help identify patients in high‐risk of developing cardiometabolic disease after BC 
treatment.
K E Y W O R D S
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estrogen receptor modulator (SERM), is the first choice for 
premenopausal women. The aromatase inhibitors stops the 
production of estrogen and acts by blocking the enzyme aro-
matase, which turns the hormone androgen into estrogen in 
the body, resulting in less estrogen and in turn impair growth 
of hormone‐receptor‐positive BC cells. The most prevalent 
types of aromatase inhibitors used in the clinic in treatment 
of postmenopausal women are anastrozole, exemestane and 
letrozole.4
It has been known since the 1970’s that women receiving 
adjuvant chemotherapy experience weight gain, commonly 
reported as 2‐5 kg but with great variance.5-7 Furthermore, 
a recent review emphasizes the important role of in partic-
ular body composition on overall health status of BC pa-
tients,8 as excess adiposity may increase mediators of not 
only BC recurrence but also of metabolic disease. Gadéa et 
al9 looked at publications on chemotherapy‐induced weight 
changes, concluding that no consensus existed on the cause 
of metabolic derangement pointing toward adipokines, in-
sulin and insulin‐like growth factor (IGF) being possible 
factors. Aromatase inhibitors, used for treatment of hor-
mone receptor‐positive BC, effect on lipid metabolism 
have been thoroughly described, demonstrating a negative 
effect on the lipid‐profile due to a lack of estrogen as op-
posed to tamoxifen which has an agonistic estrogen effect 
outside of the breast.10 Furthermore, a meta‐analysis from 
2008 demonstrated an increase in cardiovascular events 
in patients treated with aromatase inhibitors compared to 
tamoxifen,11 and a recent study found that aromatase in-
hibitors increased the risk of diabetes mellitus.12 However, 
the specific effect of chemotherapy and/or aromatase in-
hibitors on glucose and insulin metabolism is poorly under-
stood with only a limited amount of studies having focused 
on this.
Very few animal studies have examined the metabolic 
impact of chemotherapy; Story et al13 reported weight gain 
in dogs receiving carboplatin while another study found sig-
nificant increases in total and LDL cholesterol in rats when 
treated with cisplatin and oxaliplatin.14 Pivotal studies on 
humans have linked alkylating agents to hypertension15 and 
increased cholesterol,14 but metabolic factors are rarely part 
of initial drug testing. Multi‐agent regimens and longer treat-
ment duration may be factors resulting in weight gain,5,9 but 
there is in general a lack of research on long‐term metabolic 
side effects.
Altogether, studies suggest that women receiving adjuvant 
chemotherapy and/or aromatase inhibitors for BC experience 
metabolic alterations giving rise to a phenotype associated 
with increased risk of developing cardiometabolic disease 
as well as BC recurrence.9,16 The importance of improved 
F I G U R E  1  Flow chart depicting 
literature search
Records identified through database 
searching 
(n = 3227)
Records after duplicates removed 
(n = 3227)
Records screened
(n = 3227)
Records excluded
(n = 3193)
Full-text articles assessed for 
eligibility
(n = 40)
Full-text articles excluded (n = 32)
• Cross-sectional studies (7)
• Comparative studies not 
including glu/insulin (25)
Studies included in qualitative 
synthesis
(n = 8)
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understanding of long‐term impact as well as the underlying 
mechanisms is underlined by the fact that women who are free 
of disease after 5 years of tamoxifen treatment are more likely 
to die from non‐BC causes.17 However, no data exist on longer 
follow‐up times with regard to non‐BC causes of mortality.
The purpose of this systematic review is thus to assess 
the current available knowledge on impact of adjuvant che-
motherapy and/or aromatase inhibitors in women with BC 
on metabolic alterations focusing on glucose and insulin 
metabolism.
2 |  METHODS
This review has been written according to the PRISMA 
guidelines. All articles describing the effect of adjuvant 
chemotherapy and/or aromatase inhibitors in women with 
BC and how it affected glucose, insulin and/or insulin resist-
ance by comparing measurements before and after treatment 
were identified and included (Figure 1). No limits to follow‐
up time or publication date were specified in the attempt to 
get as many relevant articles as possible. Exclusion criteria 
included non‐English articles, although relevant English ab-
stracts for foreign language articles were assessed. Screening 
of articles was performed by reading titles, and if relevant 
abstracts, to find articles for full text evaluation.
We searched PubMed (Medline) on 4th of May 2018 with 
the following search terms:
(Breast Neoplasms[mh] OR Breast Neoplasm*[ti] OR 
Breast Neoplasm*[ot] OR Breast Carcinoma[ti] OR 
Breast Carcinoma[ot] OR Breast cancer[ti] OR Breast 
cancer[ot])
AND
(Oncological treatment[ti] OR Oncological treatment[ot] OR 
Antineoplastic Combined Chemotherapy Protocols[mh] 
OR Chemotherapy[ti] OR Chemotherapy[ot] OR 
Chemotherapy, adjuvant[mh] OR Adjuvant[ti] OR 
Adjuvant[ot] OR Chemoradiotherapy, adjuvant[mh] OR 
Chemoradiotherapy[mh] OR Chemoradiotherapy[ti] 
OR Chemoradiotherapy[ot] OR Neoadjuvant 
Therapy[mh] OR Neoadjuvant[ti] OR Neoadjuvant[ot] 
OR Antineoplastic Agents, Hormonal[mh] OR 
Aromatase Inhibitors[mh] OR Aromatase Inhibitors[ti] 
OR Aromatase Inhibitors[ot] OR Tamoxifen[mh] OR 
Tamoxifen[ti] OR Tamoxifen[ot] OR Raloxifen[mh] OR 
Raloxifen[ti] OR Raloxifen[ot])
AND
(Body composition[mh] OR Body composition[ti] OR Body 
composition[ot] OR Body Weights and Measures[mh] 
OR Diabetes[ti] OR Diabetes[ot] OR Dyslipidemias[mh] 
OR Dyslipidemia*[ti] OR Dyslipidemia*[ot] OR Fat 
percentage[ti] OR Fat percentage[ot] OR Glucose 
Intolerance[mh] OR Glucose Intolerance[ti] OR Glucose 
Intolerance[ot] OR Hypercholesterolemia*[ti] OR 
Hypercholesterolemia*[ot] OR Hyperglycemia*[ti] OR 
Hyperglycemia*[ot] OR Hypertriglyceridaemia*[ti] OR 
Hypertriglyceridaemia*[ot] OR Insulin[ti] OR Insulin[ot] 
OR Insulin Resistance[ti] OR Insulin Resistance[ot] OR 
Insulin Sensitivity[ti] OR Insulin Sensitivity[ot] OR 
Metabolic Disease[mh] OR Metabolic syndrome[ti] 
OR Metabolic syndrome[ot] OR Metabolism[mh] 
OR Metabolism[ti] OR Blood glucose[mh] OR Body 
Mass Index[mh] OR Metabolic syndrome[mh] OR 
Metabolic syndrome[ti] OR Metabolic syndrome[ot] OR 
Triglycerides[mh] OR Waist‐Hip Ratio[mh])
3 |  RESULTS
As shown in Figure 1, the search yielded in total 3227 arti-
cles, which were screened for eligibility, 3193 articles were 
excluded due to lack of information regarding metabolic 
factors during adjuvant chemotherapy and/or aromatase in-
hibitors of BC. Forty articles were further assessed for eli-
gibility and 32 excluded due to either being cross‐sectional 
studies (N = 7) or not including measures of glucose/insulin 
(N = 25). The eight studies included in the systematic review 
are presented in Table 1.
Adjuvant chemotherapy regimen varied between stud-
ies; four of the studies used a combination of an alkylating 
agent (cyclophosphamide or carboplatin) along with anthra-
cyclines (doxorubicin or epirubicin) and taxanes (docetaxel 
or paclitaxel). Chala et al use a regimen of alkylating agent 
with anthracyclines and fluorouracil and Hickish et al vary 
between both of the abovementioned combinations. Two 
studies do not specify treatment. In three of the studies it is 
indicated that some patients received endocrine treatment, 
Dieli‐Conwright et al18 uses a regimen including trastuzumab 
in 6% of patients, Guinan et al19 state that patients may have 
received trastuzumab and Arpina et al20 followed chemother-
apy with endocrine treatment in most patients without further 
clarification.
The eight articles were published between 2006 and 2016, 
with a prospective study design in six and a retrospective 
study design in the two remaining studies. The general trend 
of the studies was to use measurements from before the first 
cycle of chemotherapy and compare to measurements during 
or shortly after the last cycle. The follow‐up periods range 
from 3 to 40 months, but with only two studies having an 
average follow‐up time of more than 7 months. Four of the 
studies reported a significant increase in weight/BMI whereas 
three studies did not find a significant change in body weight 
(Table 1). However, likely due to the short follow‐up times, 
only marginal weight gain is reported, with the exception of 
Dieli‐Conwright et al18 who reported an increase of 5.5 kg.
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Study size ranged from 10 to 433 patients, where only 
three studies included more than 50 patients. BC stage was 
not reported in three studies, where the remaining studies in-
cluded stage I‐III patients, with only one study exclusively 
examining stage IV BC patients. The studies included both 
pre‐ and postmenopausal women, with the exception of one 
study exclusively including postmenopausal women and one 
study not specifying menopausal state. The mean age ranged 
from 48.2‐63.2 years.
Blood glucose or hemoglobin A1c (HbA1c) was measured 
in all studies. HbA1c is a measure of glycation of hemoglo-
bin, and as red blood cells have a lifespan of up to 120 days, it 
represents a measure of the average blood glucose concentra-
tion during the past 8‐12 weeks. Most studies found no sig-
nificant change from before to after adjuvant chemotherapy 
and/or aromatase inhibitors. However, two studies found a 
significant increase in glucose and HbA1c respectively18,19 
and one found a significant increase in a subgroup treated 
with dexamethasone.21
Insulin was measured in six studies and was significantly 
increased after adjuvant chemotherapy in four of these. 
Contrary to this Chala et al found a significant decrease in in-
sulin at 120 minutes during an oral glucose tolerance (OGTT) 
test compared to before adjuvant therapy. Homeostatic model 
assessment of insulin resistance (HOMA‐IR) was calculated 
in five of the studies, and was significantly increased in four 
of the studies.18,19,22,23
4 |  DISCUSSION
4.1 | Summary and limitations
Although only a limited number of studies have looked at 
the impact of adjuvant chemotherapy and/or aromatase in-
hibitors on glucose and insulin metabolism in women with 
BC, it appears that a negative effect is the most common ob-
servation. The eight studies in focus do have severe limita-
tions. The short follow‐up times make it difficult to predict 
long‐term consequences of metabolic changes. Likewise, are 
several of the studies small in sample size and some are ret-
rospective studies.
The pre‐ and post‐treatment weight and/or BMI were 
reported in seven of the eight studies. Four of the studies 
reported a significant increase in weight and/or BMI in re-
sponse to treatment.18,20,23,25 The women included in the 
studies had a pretreatment BMI >25 kg/m2 which correspond 
with the fact that increased weight, is a risk factor of BC. 
However, none of the studies included a control group, thus 
no comparable background information including weight and 
BMI exist on aged‐matched women without BC.
Weight gain is common among aging women, especially 
during the menopausal transition. According to several 
studies, the average weight gain in women during midlife 
is approximately 0.4‐0.7 kg/y independent of initial body 
weight and ethnicity, however with a large individual varia-
tion.26,27 This information is important to keep in mind when 
evaluating the effect of chemotherapy and hormonal treat-
ment in women with BC.
The generalizability of the studies to current BC patients 
is limited by the differing treatment, with only four studies 
using regimens that reflect current practice with the com-
bination of an alkylating agent combined with an anthracy-
cline and a taxane. Furthermore, many studies lack detailed 
descriptions concerning treatment, especially with regard to 
endocrine treatment. The adverse effects on metabolism are 
poorly understood and rarely the focus in clinical or animal 
studies of chemotherapy effect in cancer. Finally, has weight 
gain not been clearly linked to any specific regimen or single 
chemotherapeutic agent.9
4.2 | Duration of metabolic derangement
The long‐term effects of metabolic changes induced by 
chemotherapy are difficult to assess, but in a study of more 
than 3000 women Saquib et al29 found that only 10% returned 
to their pre‐BC diagnosis weight over a 6‐year period.
Among the studies on the glucose metabolism, only two 
have follow‐up periods of more than a year, with Guinan et 
al19 having follow‐up periods of up to 40 months showing an 
increase in HbA1c, insulin and HOMA. Arpino et al,20 on a 
much larger cohort found no significant change in glucose or 
insulin with an average follow‐up time of 14 months. Several 
studies have tried to examine if the negative effect could po-
tentially lead to an increase in diabetes diagnoses. Lipscombe 
et al30 found an increase in diabetes incidence from 2 years 
post surgery. This is substantiated by other studies,12,31 al-
though some find no significant change in incidence.32
4.3 | Potential mechanisms
The underlying cause of the metabolic alterations including 
changes in glucose and insulin metabolism is not clear and 
are most likely only part of the metabolic changes occurring 
as a consequence of adjuvant chemotherapy and/or aromatase 
inhibitors of BC patients. However, the previously mentioned 
weight gain and/or changes in body composition are likely to be 
factors contributing to the metabolic changes. Weight change 
during chemotherapy may be caused by treatment‐related side‐
effects such as fatigue, physical inactivity, sarcopenia and al-
tered appetite. The increase in circulating lipids18 could also 
be the cause for changes in glucose metabolism. Alternative 
mechanisms include reduced basic metabolic rate33 as well as 
changes in the circadian rhythm in response to chemotherapy.34
It is likely that certain subgroups may be at increased 
risk of unfavorable changes in body composition follow-
ing chemotherapy. Previous studies have suggested that 
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premenopausal women may gain more weight during treat-
ment of BC than postmenopausal women8 and that women 
with low body weight at diagnosis may gain more weight at 
the start of treatment than overweight women.35 The weight 
gain is primarily of adipose tissue with a tendency to lose 
muscle mass also known as sarcopenic obesity.8
Adiposity may increase the risk of metabolic disease, and 
in recent years adipokines and primarily leptin has been inves-
tigated. Leptin is a hormone produced in the fat tissue and is 
positively correlated with body fat mass.36 Several studies have 
tested if adjuvant chemotherapy and/or aromatase inhibitors 
affects leptin production, and while most find no significant 
change22,23 others find high leptin levels linked to tamoxifen 
as well as raloxifene use.37,38 Akyol et al39 shows a significant 
increase in leptin during aromatase inhibitor and tamoxifen 
treatment, but also an increase in the antagonistic adipokine 
adiponectin making the clinical effect unclear. Low levels of 
adiponectin have been linked to increased BC mortality.40
Interleukins has been shown by Paz et al41 to be affected 
by chemotherapy, as they found that despite IL‐6 being in-
creased and IL‐10 being decreased compared to controls be-
fore treatment; chemotherapy further enhanced this tendency. 
Another study found no change in interleukins, including 
IL‐6, during adjuvant chemotherapy and/or treatment with 
aromatase inhibitors.24 Fibroblast growth factor 21 (FGF‐21) 
was decreased during aromatase inhibitor and tamoxifen 
treatment suggesting a positive effect on metabolism.39 It is 
also worth noting that certain genetic polymorphisms have 
been linked to loss of fat free mass during aromatase inhibitor 
treatment,42 suggesting that a subgroup of patients could be 
more susceptible to metabolic adverse effects.
4.4 | Consequences
With obesity being an independent risk factor for develop-
ment of BC in postmenopausal women,43,44 BC patients, as 
a group, are in a worse metabolic condition than a compar-
ative group of women.45,46 Therefore, a further metabolic 
derangement of this group of patients, with an otherwise 
high survival rate,2 could potentially cause cardiometa-
bolic disease in the future. This is highlighted by cross‐sec-
tional studies showing an increase in metabolic syndrome 
of postmenopausal BC survivors compared to healthy con-
trols47 and increased visceral adipose tissue due to tamox-
ifen use.48 Cheney et al49 found that regardless of weight 
gain or loss, women receiving adjuvant chemotherapy and/
or aromatase inhibitors for BC were likely to gain fat mass 
and lose lean body mass.
4.5 | Prevention of adverse metabolic effects
Exercise training and dietary interventions have been 
suggested to alleviate or minimize treatment‐related side 
effects to BC. Recent systematic reviews and meta‐anal-
ysis have shown significant effects of physical exercise 
on anthropometric measures and quality of life.50,51 The 
ENERGY study is the largest weight loss intervention trial 
among survivors of BC to date, including both dietary guid-
ance and physical activity to promote weight loss over a 
2 year period, resulting in a ~4% weight loss among elderly 
overweight or obese women.52 However, interpretation of 
most results from exercise and dietary intervention studies 
must be done with caution because of relatively poor qual-
ity of evidence, methodological limitations, low numbers 
and short follow‐up time etc Further well‐designed studies 
are therefore required to determine the impact of exercise 
and dietary interventions on treatment‐related side‐effects. 
Moreover, follow‐up studies are particularly required be-
cause of possible long‐term side effects of adjuvant treat-
ment of BC.
5 |  CONCLUSION
Women undergoing medical treatment for BC, appear to 
become metabolically deranged to some extent. This is 
mainly evident by a small increase in weight and/or change 
in body composition, but the underlying mechanism has not 
yet been thoroughly described. Earlier explanations like 
overeating,53 seem unlikely on its own, due to the loss of 
lean body mass and development of sarcopenic obesity.54 
A combination of fatigue, physical inactivity, altered ap-
petite and sarcopenic obesity having a negative impact on 
especially the insulin and glucose metabolism appear to 
be the most likely explanation. The studies in this field 
are few and of varying quality, which is why larger stud-
ies over a longer duration is needed, as well as studies on 
patients using up‐to‐date BC treatment regimens. Because 
of observed treatment‐related changes in body composi-
tion, physical activity as also recommended during treat-
ment and recovery, as it might indeed be beneficial for this 
patient group to overcome metabolic derangements.
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